Engineered Calprotectin-Responsive Probiotics for Inflammatory Bowel Disease Treatment
ACS Synthetic Biology · 2026
DOI: 10.1021/acssynbio.6c00347 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Synthetic Biology, 2026. Verfasst von Fan Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei430071, China. Hauptthemen laut MEDLINE: Probiotics, Leukocyte L1 Antigen Complex, Inflammatory Bowel Diseases. Die Arbeit nennt 61 Literaturangaben. Gefördert von: Hubei Jiangxia Laboratory Open Foundation, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Inflammatory bowel disease (IBD) is a complex intestinal disorder for which effective treatment options remain limited. The modulation of gut microbiota balance using probiotics holds promise as a therapeutic approach to restore intestinal microenvironment homeostasis. However, the clinical translation of conventional probiotics is constrained by the suboptimal therapeutic efficacy. Here, we constructed a recombinant Escherichia coli Nissle 1917 strain (EcN-CR-IL2) based on an optimized calprotectin-responsive ykgMO promoter to achieve inflammation-dependent expression of the immunomodulatory cytokine interleukin-2 (IL-2), which selectively expands regulatory T cells to suppress aberrant intestinal inflammation. The optimized promoter achieved approximately 100-fold greater induction than the native ykgMO promoter and responded robustly to calprotectin both in vitro and in a DSS-induced murine colitis model in vivo. Oral administration of EcN-CR-IL2 significantly alleviated colitis symptoms in both prophylactic and therapeutic settings, suppressed proinflammatory cytokine levels, restored intestinal barrier integrity, and shifted gut microbiota composition toward a more homeostatic profile. Importantly, the therapeutic output of EcN-CR-IL2 correlated with local calprotectin levels, enabling on-demand modulation of anti-inflammatory effects in response to disease progression. This study presents a probiotic delivery system that combines real-time sensing of a clinically validated biomarker with autonomous therapeutic production, providing a new approach for the treatment of chronic intestinal inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei430071, China.
- University of Chinese Academy of Sciences , Beijing100049, China.
- Hubei Jiangxia Laboratory, Wuhan430200, China.
ORCID-Profile: Yangbo Hu
Förderung
- Hubei Jiangxia Laboratory Open Foundation
- China Postdoctoral Science Foundation
Zitieren
APA
Yang, F., He, L., Lin, X., Huang, X., Hu, Y., Chen, M., Wu, Z., Xi, J., Lu, X., Li, M., & Hu, Y. (2026). Engineered Calprotectin-Responsive Probiotics for Inflammatory Bowel Disease Treatment. ACS Synthetic Biology. https://doi.org/10.1021/acssynbio.6c00347
Vancouver
Yang F, He L, Lin X, Huang X, Hu Y, Chen M, et al. Engineered Calprotectin-Responsive Probiotics for Inflammatory Bowel Disease Treatment. ACS Synthetic Biology. 2026. doi:10.1021/acssynbio.6c00347
BibTeX
@article{Yang2026,
author = {Yang, Fan and He, Lina and Lin, Xian and Huang, Xindi and Hu, Yuefeng and Chen, Min and Wu, Zhiyong and Xi, Jiayang and Lu, Xiaoxiao and Li, Mengke and Hu, Yangbo},
title = {Engineered Calprotectin-Responsive Probiotics for Inflammatory Bowel Disease Treatment},
journal = {ACS Synthetic Biology},
year = {2026},
doi = {10.1021/acssynbio.6c00347}
}
EUVIMED